Title:
NPP1 fused protein
Document Type and Number:
Japanese Patent JP6096826
Kind Code:
B2
Abstract:
The present invention provides a novel fusion polypeptide containing a catalytic domain of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.
Inventors:
Quinn, Anthony
Harvey, Alex Jay.
Shea, Chinan
Harvey, Alex Jay.
Shea, Chinan
Application Number:
JP2015084216A
Publication Date:
March 15, 2017
Filing Date:
April 16, 2015
Export Citation:
Assignee:
Synageva BioPharma Corp.
International Classes:
C12N15/09; C07K19/00; C12N9/16
Other References:
J. Bone Miner. Res., (2003), 18, [6], p.994-1004
Curr. Opin. Biotechnol., (2009), 20, [6], p.692-699
Trends Biotechnol., (1996), 14, [2], p.52-60
Fusion-proteins as biopharmaceuticals--applications and challenges. [online]. 2009 uploaded. NCBI PubMed, PMID:19333874 [Retrieved on 2016-MAR-04]. Retrived from the internet:
Curr. Opin. Biotechnol., (2009), 20, [6], p.692-699
Trends Biotechnol., (1996), 14, [2], p.52-60
Fusion-proteins as biopharmaceuticals--applications and challenges. [online]. 2009 uploaded. NCBI PubMed, PMID:19333874 [Retrieved on 2016-MAR-04]. Retrived from the internet:
Attorney, Agent or Firm:
Patent business corporation Kita Aoyama International